The Unsung Heroes of the Biotechnology Revolution: Who Made Australia the Top Destination for Clinical Trials and Biomedical Research?

Australia built the fastest, most trustworthy early-clinical system in the world through decades of unglamorous policy work. The world should know its heroes 🫡

_{This article is not an investment advice or drug recommendation. Generative AI tools were used in both research and editing of this document.}

During the opening of #BIO2026 in San Diego on June 22nd, I was invited to take part in the Australian Government AI in Drug Development Industry Roundtable featuring Dr. Jiye Shi, Sr. VP, Discovery Technology & Platforms and Early Molecule Discovery, Eli Lilly, and Professor Pall Thordarson, Director of the UNSW RNA Institute, as guest speakers. This event brought together many leaders in biotechnology and AI-powered drug discovery.

We discussed the benefits of Australia as a biotechnology hub, but few delegates remembered how this country became the go-to place for biotechnology and clinical development. In my opinion, many books must be written about the history of this transformation, and the true heroes must be celebrated. Biotechnology companies and patient organizations should consider erecting a monument to the policymakers of the past and present who helped shave six months to a year off the drug discovery and development cycle, a process that typically takes 10–15 years.

Half a year or a year may not sound like much, but it certainly matters to a young mother of several children suffering from a terminal illness that could become treatable or manageable as a chronic condition, or to the elderly battling dementia before it becomes irreversable.

If you give one additional year of life to everyone on the planet, you generate roughly 8.3 billion life-years, equivalent to over 100 million lifetimes. That is more lifetimes than the number of humans killed in all wars ever fought combined. So if there is someone up there keeping count, any policymaker who saves so many lives deserves to go to heaven. Or at least, deserves to be remembered. I hope that there is also hell for those who intentionally slow things down by creating barriers for personal gain or simply to get some attention. This is the rule of thumb I use for my own decision making - one year delay or acceleration for the longevity therapeutic that can give everyone one year of life is equivalent to 100 million lifetimes.

One of the strategies for developing longevity therapeutics is to identify dual-purpose drugs that help patients with chronic disease but also target the fundamental pathological processes that also drive aging. For chronic diseases, Australia is one of Insilico Medicine’s prime destinations for clinical trials. This is not because Australia offers regulatory shortcuts. It is because Australia built something far more valuable: a system that can move quickly while preserving Good Clinical Practice, credible institutional review, and data quality that global regulators can evaluate.

Insilico Medicine is a genuinely global, multi-hub AI drug discovery company. We operate out of Boston, Montreal, Abu Dhabi, Hong Kong, and Shanghai, with operations and partnerships spanning Asia, the Middle East, Europe, and North America. Our scientific and clinical programs move through the jurisdictions best suited to each stage, from target discovery and chemistry to manufacturing, first-in-human studies, and later-phase development. Humans are single species regardless of color, gender, age, or nationality, and our job is to produce safe and effective therapeutics to extend healthy productive life for everyone on the planet (we also want to make animals live longer but this is a subject for another story).

Over the past five years, our platform and drug discovery teams have nominated 31 preclinical or development candidates, secured 13 investigational new drug clearances or equivalent authorizations, advanced eight programs into Phase 1, three into Phase 2, and one into Phase 3. Many companies in AI drug discovery struggle to deliver one high-quality developmental candidate in one area while claiming to make therapeutics faster, cheaper and higher probability of success. But Insilico is the “MMA Fighter” working on fibrosis, immunology and inflammation, neuroinflammation, neuroimmunology, oncology, cardiovascular diseases, obesity, CKD, pain and other areas in order to increase the chances of developing longevity therapeutics that target aging at its core. This commitment to high productivity, organizational resilience and sustainability force a company to study regulatory systems empirically. When multiple programs are moving in parallel, small differences in review time, operating cost, site quality, and tax treatment compound into years of productive life and hundreds of millions of dollars across a portfolio.

Australia consistently stands out. Its advantage is the result of deliberate policy choices made over several decades, beginning with foundational therapeutic goods legislation and maturing through the modern Therapeutic Goods Administration, the Clinical Trial Notification scheme, an experienced Human Research Ethics Committee network, and a refundable research and development tax incentive. These systems did not appear spontaneously. They were built by ministers, physicians, reviewers, civil servants, ethics committees, investigators, and institutions whose names rarely appear in biotechnology narratives.

Why Australia Works for Early Clinical Development

The central mechanism is the Clinical Trial Notification, or CTN, scheme administered by the Therapeutic Goods Administration, the TGA. Under the CTN pathway, the sponsor does not generally wait for the TGA to conduct a full upfront review of the clinical dossier before a trial can begin. Scientific and ethical assessment is conducted through the responsible Human Research Ethics Committee, or HREC, together with governance authorization from the participating institution, while the TGA is notified of the trial.

That distinction has enormous operational consequences. A well-prepared submission can often move through HREC review in approximately four to six weeks, although actual timelines depend on the committee, institution, protocol complexity, meeting calendars, and responses to questions. Site governance and contracting can add time, as they do in every country, but the path can still be measured in months to first dosed patient rather than years.

The CTN system does not eliminate accountability. Sponsors remain responsible for the quality of the investigational product, the adequacy of nonclinical evidence, protocol design, safety monitoring, reporting, and compliance with applicable standards. Investigators and institutions must be satisfied that the study is scientifically and ethically defensible. The HREC has substantive responsibility, not a ceremonial role.

This is a more sophisticated model than the caricature of either full centralized control or deregulation. Australia allocates review to institutions capable of evaluating the actual trial and its local context, while retaining national regulatory authority, safety reporting obligations, inspection powers, and the possibility of using the Clinical Trial Approval pathway where direct TGA evaluation is appropriate. Speed comes from institutional design, not from pretending risk does not exist.

The Economics Are Equally Important

Australia’s R&D Tax Incentive materially changes the economics of development. For eligible companies with aggregated turnover below A$20 million, the program can provide a refundable tax offset of 43.5 percent for eligible research and development expenditure, subject to the detailed rules and exclusions that govern the scheme. The refundable structure has been in place since 1 July 2011, replacing the previous concession framework.

For biotechnology companies, refundability matters more than a conventional tax deduction. Early-stage drug developers commonly operate at a loss for years because clinical programs consume cash before producing revenue. A deduction against profits that do not yet exist has limited immediate utility. A refundable offset can return capital to the development cycle, allowing a company to finance additional experiments, cohorts, formulations, or programs.

The scheme also does not generally impose an IP-localization requirement as the price of accessing the incentive. Eligibility turns on the statutory criteria for the entity and the R&D activities, not on transferring ownership of the entire intellectual property estate to Australia. Companies still need competent Australian tax and legal advice because related-party arrangements, overseas activities, expenditure categories, registration, substantiation, and corporate structure can change the result.

Taken together, the CTN pathway and the R&D Tax Incentive can make a well-run Phase 1 study in Australia approximately 60 percent less expensive than an equivalent program in the United States or parts of Europe. This figure should be treated as an operating benchmark rather than a universal tariff. The exact difference depends on indication, design, biomarker burden, recruitment, manufacturing, central laboratories, foreign exchange, and what costs are included.

Yet the directional advantage is real. Australia combines lower net cost with GCP-quality data that can be used in global development programs and accepted for review by authorities such as the United States Food and Drug Administration, the European Medicines Agency, and Japan’s Pharmaceuticals and Medical Devices Agency, provided the study itself and the broader dossier satisfy their requirements. No serious sponsor should assume automatic acceptance, but Australia is not an isolated regulatory island.

Why Chronic Disease Programs Fit Australia

Australia has a diverse, urbanized, and medically well-characterized population with substantial prevalence of chronic diseases associated with aging, metabolic dysfunction, fibrosis, cancer, and immune dysregulation. It has experienced principal investigators, reputable universities, high-quality hospitals, specialist trial units, and a clinical workforce accustomed to multinational development standards. English-language source documentation and established links to global sponsors reduce operational friction.

For early studies in healthy volunteers, Australia has a mature network of specialist Phase 1 units. For patient studies, the relevant advantage is not simply the existence of patients. It is the combination of patients, investigators who understand protocol-intensive research, reliable diagnostic infrastructure, biospecimen handling, and institutions capable of producing auditable records.

This matters a lot to me because our objective is not to produce an attractive press release after target discovery. It is to translate computational hypotheses into medicines. In my academic work and in building our pipeline, I have repeatedly emphasized that generative chemistry and target identification are only the beginning. Biology, pharmacology, manufacturing, clinical operations, and human evidence determine whether an algorithmically generated idea becomes a drug.

Our rentosertib program, directed at TNIK and studied in idiopathic pulmonary fibrosis, is a useful example of that progression. The program moved from an AI-enabled discovery process into clinical development (originally, the First-in-Human study was performed in Australia), and the Phase 2a GENESIS-IPF results were published in Nature Medicine and it progressed into Phase 3 in China. The point is not that artificial intelligence abolishes clinical development. The point is that AI can compress and improve portions of discovery, then hand the molecule to the same demanding human system of ethics, dosing, safety, measurement, and regulatory scrutiny faced by every serious drug program.

I explored this constraint in Can We Accelerate Drug Discovery Faster? and again in AI Drug Discovery Dreams: How Fast Can a Drug Really Be Approved?. Algorithms can generate targets and molecules rapidly. Human trials remain sequential, expensive, highly regulated, and ethically constrained. Countries that reduce avoidable administrative latency without reducing scientific or ethical rigor therefore become central infrastructure for the global biotechnology industry.

The Policy History Behind the Advantage

Australia’s present system is the product of cumulative institutional development. It should not be credited to one administration, one agency, or one reform. Still, some individuals made decisions that were unusually consequential, and Peter Staples deserves a much larger place in this history than he usually receives.

Peter Staples and the Creation of the CTN Scheme

The Hon Peter Staples was the federal Minister for Aged, Family and Health Services when he announced the Clinical Trial Notification scheme in February 1991. This was a remarkably consequential policy decision. The scheme created a practical route through which clinical research could proceed following local scientific and ethical review and notification to the national regulator, rather than requiring every qualifying trial to wait for a full centralized pre-market style assessment.

Staples also commissioned the review led by Peter Baume. This matters because good reform requires more than announcing a faster pathway. It requires exposing the system to independent criticism, examining the distribution of responsibility, and asking whether the balance between access, innovation, safety, and ethics is defensible.

Political leaders are often rewarded for launching large spending programs with visible buildings and immediate constituencies. Regulatory architecture is less photogenic. Yet a well-designed review pathway can influence thousands of studies, attract international capital, train investigators, strengthen hospitals, and accelerate access to experimental medicines over several decades.

Staples deserves genuine credit for understanding that clinical research capacity could be increased through governance design. He did not need to weaken the regulator. He needed to clarify which decisions should be made nationally, which should be made by expert ethics committees, and how responsibility should be documented. We now see similar thinking in the US at the state level (e.g. in Montana but more on this later) and other countries.

Peter Baume and A Question of Balance

Professor Peter Baume led the 1991 review commonly known as A Question of Balance. The review produced 164 recommendations covering clinical trials and related ethical and regulatory questions. Its title captured the central problem accurately: the system had to protect participants while enabling research that could benefit future patients.

Baume brought unusual credibility to the task. He had experience in medicine, public policy, and federal politics, including service as a health minister. That combination matters because clinical trial regulation cannot be designed solely as an abstract legal exercise. It must account for bedside realities, institutional incentives, scientific uncertainty, and the legitimate pressure to develop better treatments.

The review should not be reduced to a ceremonial endorsement of the CTN concept. Its value lay in examining the machinery around clinical research and proposing a broad program of reform. Some recommendations were implemented, others evolved through later policy, and parts of the system continued to be debated. That is normal for a review of such scope.

What endured was the idea that participant protection and research efficiency are not inherently opposing objectives. A process can be faster because responsibility is allocated more intelligently. It becomes dangerous only when speed is purchased by hiding risk, lowering evidence standards, or making oversight fictitious.

Richard Day and the 1993 Stress Test

A subsequent review led by Professor Richard Day in 1993 examined the early operation of the new arrangements. It effectively stress-tested the CTN framework after implementation and helped preserve the notification model rather than allowing early concerns to trigger a return to universal centralized review. Historical summaries differ in how they characterize the exact remit and influence of this review, so the safest interpretation is that it formed part of the early evaluation and consolidation of CTN.

This kind of follow-up is essential. New regulatory systems inevitably encounter inconsistent institutional capacity, uncertainty about roles, and cases that expose ambiguities. The rational response is to improve governance and guidance, not automatically to rebuild the slowest possible process.

Day’s contribution deserves recognition because preserving a useful reform can be as difficult as creating it. Regulatory innovation often survives its first political battle and then dies through administrative accretion. Each additional form, duplicated review, or ambiguous approval layer appears defensible in isolation until the original advantage disappears.

Australia largely avoided that outcome in early-phase clinical development. It retained a credible notification pathway while continuing to develop ethics guidance, institutional governance, adverse event reporting, and national regulatory oversight. The result was a system that international sponsors could learn and trust.

Ethics Committees Are Regulatory Infrastructure

The HREC network is sometimes described as if it were merely the local paperwork component of CTN. That interpretation is wrong. Delegation works only when the receiving institutions have competence, independence, clear responsibilities, and the authority to reject or modify a study.

Australian HRECs review the ethical acceptability of research involving humans, informed by the National Statement on Ethical Conduct in Human Research and related guidance. They consider consent, risk, participant selection, scientific merit, privacy, data handling, compensation, and the suitability of the investigator and site. In practice, scientific review and governance may involve additional institutional bodies, but the HREC remains central.

The system is not frictionless. Sponsors can encounter duplication between institutions, inconsistent document requirements, differing interpretations, and delays in site-specific governance after ethics approval. Multicenter research can still be slowed by contracts, indemnities, budgets, pharmacy reviews, biosafety questions, and information technology controls.

Australia’s policy challenge is therefore not to replace CTN with a heavier centralized model. It is to improve harmonization, mutual recognition, digital submissions, standard contracts, national consistency, and transparency around review timelines. Current reform efforts aimed at a more connected national clinical trials system, including greater consistency across jurisdictions and institutions, deserve support if they reduce duplication while preserving meaningful review.

The Tax Incentive Is Industrial Policy

Governments often prefer to describe research tax incentives as neutral features of the tax system. In practice, they are industrial policy. They influence where companies employ scientists, contract laboratories, run trials, build data packages, and establish long-term institutional relationships.

Australia’s refundable structure is unusually relevant to biotechnology because it recognizes the economic profile of research-intensive, pre-revenue companies. A clinical-stage company may create substantial intellectual and social value while recording accounting losses. If tax support arrives only after profitability, it arrives too late for many firms.

The lack of a blanket IP-localization requirement is equally rational. Modern drug discovery depends on distributed ownership, licensing, contract research, multinational financing, and cross-border development rights. Forcing a sponsor to relocate core intellectual property merely to run an Australian study would deter activity and invite artificial structures.

Australia instead competes for real R&D activity. That is the correct target. Trials employ clinicians, nurses, pharmacists, coordinators, laboratory staff, data managers, quality specialists, and statisticians. They build investigator experience, provide institutions with advanced research infrastructure, and give the local medical community earlier exposure to emerging therapeutic modalities.

The incentive must still be policed. Refundable programs can attract aggressive claims, weak substantiation, or attempts to characterize routine commercial work as eligible research. Maintaining integrity protects the political durability of the system. A generous program that loses public trust will eventually be restricted, regardless of its scientific value.

Drug Discovery Has No Single National Flag

Public discussion increasingly treats biotechnology as a contest in which one country must own the entire stack. That is politically convenient and scientifically inaccurate. No country has an uncontested monopoly over target discovery, medicinal chemistry, structural biology, translational models, manufacturing, clinical pharmacology, patient recruitment, regulatory science, and commercial launch.

Clusters form where capabilities are strongest. One jurisdiction may excel in machine learning and computational biology. Another may have exceptional synthetic chemistry and contract research capacity. A third may dominate complex manufacturing. Australia may offer the best combination of speed, quality, and economics for a particular early clinical program, while later-phase enrollment is distributed across several continents.

Insilico was built around this reality. We are a global company headquartered across Boston, Montreal, Abu Dhabi, Hong Kong, and Shanghai. Our operations and partnerships span Asia, the Middle East, Europe, and North America because diseases do not have nationalities and everyone has aging.

Global development does not mean regulatory arbitrage. A study performed in one country must be capable of surviving scrutiny in others. Data integrity, trial conduct, manufacturing controls, assay validation, and safety reporting must travel across borders. The most valuable clinical jurisdictions are those that can move quickly and still produce evidence that skeptical external regulators regard as credible.

Collaboration and Competition Can Coexist

Countries should collaborate on scientific standards, data interoperability, adverse event reporting, trial registration, bioethics, and the recognition of high-quality evidence. Fragmentation imposes costs without necessarily improving safety. Patients lose when sponsors repeat work solely because regulators cannot communicate or accept compatible standards.

At the same time, countries legitimately compete to host parts of the development pipeline. They compete on review speed, investigator quality, cost, predictability, hospital infrastructure, tax treatment, and access to relevant patient populations. This competition is healthy when it rewards administrative competence and scientific rigor.

The wrong competition lowers safety standards, hides adverse events, tolerates weak consent, or allows low-quality data. The right competition removes idle time, duplicated review, unpredictable contracting, and bureaucratic ambiguity. A country should seek to become the fastest trustworthy jurisdiction, not merely the fastest jurisdiction.

Australia has demonstrated that these objectives can coexist. Its early clinical advantage does not come from asking fewer serious questions. It comes from allowing qualified bodies to ask those questions in parallel and close to the site where the research will occur.

From AI Speed to Clinical Reality

Our pipeline statistics illustrate the advantages of truly global operation. In five years, 31 preclinical or development candidates, 13 INDs or equivalent clearances, eight Phase 1 programs, three Phase 2 programs, and one Phase 3 program represent a cadence that would have been difficult to imagine for a company with our level of resources and the number of people under the traditional sequential model.

AI can increase the number of credible programs reaching the development boundary. It can help prioritize targets, generate molecules, optimize properties, integrate multi-omics data, and reduce cycles of synthesis and testing. This does not remove attrition. It changes where the bottleneck appears.

As discovery accelerates, clinical entry becomes a dominant constraint. A six-month avoidable delay replicated across ten programs is not six months. It is five program-years of lost experimental time. If the delay also consumes cash that could have supported another trial, the opportunity cost becomes larger.

Australia understood the value of reducing this latency before generative AI drug discovery existed. The CTN scheme was announced in 1991, when computational power, genomic data, and medicinal chemistry looked entirely different. Yet the architecture is well suited to the current moment because it is based on a durable principle: competent decentralized review can increase throughput without abandoning accountability.

This is why historical policy deserves attention from technologists. The performance of an AI-enabled biotechnology company depends on institutions designed by people who may never have written a line of code or trained a model. A molecule generated in a modern computational laboratory still passes through a regulatory channel shaped by ministers and reviewers working more than three decades ago.

What Australia Should Improve Next

Australia should defend the core logic of CTN while reducing the remaining fragmentation around it. Ethics review can be rapid, yet site activation may still be delayed by local governance, contracts, indemnity negotiations, privacy assessments, pharmacy requirements, and repeated institutional review. These layers should be examined with the same seriousness once applied to the original regulatory bottleneck.

Greater national harmonization would help multicenter studies. Mutual recognition mechanisms already exist in various forms, but practical consistency remains incomplete across states, territories, health services, and institutions. A sponsor should not have to relitigate substantially identical scientific and ethical issues at every participating site.

Digital infrastructure also matters. Standardized submissions, interoperable systems, reusable sponsor and investigator credentials, transparent status tracking, and common document templates can remove weeks of manual work. Automation should be applied first to administrative repetition, not to ethical judgment.

Australia also needs to preserve the competitiveness of the R&D Tax Incentive. Governments will always face pressure to narrow refundable programs during budget cycles. Any reform should distinguish between strengthening integrity and weakening the economic logic that makes Australia attractive to pre-revenue biotechnology companies.

Finally, Australia should measure its performance publicly. Median times from complete submission to ethics decision, governance authorization, CTN notification, contract execution, and first patient dosed would allow institutions to identify bottlenecks. Transparent benchmarking would reward high-performing sites and discourage the normalization of administrative delay.

Credit to the Officials Maintaining the System Today

Historical praise is easy because the political risks have expired. Current stewardship is harder. The federal health portfolio, led at the time of writing by Health and Aged Care Minister Mark Butler, carries responsibility for maintaining a regulatory system under pressure from new modalities, increasingly international trials, and legitimate public expectations of safety and transparency.

The TGA deserves specific credit for preserving a risk-based clinical trial framework while participating in international regulatory cooperation. Its value is not measured by the number of applications it can delay. It is measured by whether it protects participants, responds to safety signals, communicates requirements, and enables high-quality evidence to be generated efficiently.

Australia’s HRECs deserve similar recognition. They perform difficult work under time pressure, often confronting incomplete evidence and complex protocols. Their willingness to accept real responsibility is what makes the CTN model possible.

The investigators, research nurses, pharmacists, coordinators, governance officers, and institutional administrators maintaining trial quality are also part of this policy system. A statute may authorize a pathway, but people turn it into trustworthy data. Their performance is one reason global sponsors return.

Federal and state efforts to build a more interconnected national clinical trials environment are moving in the right direction where they target duplicated review, inconsistent governance, and weak data infrastructure. The test should remain practical: do reforms shorten reliable time to study activation while strengthening participant protection and data quality?

The Strategic Lesson for Other Countries

Many governments want to become biotechnology hubs. They announce funds, construct incubators, subsidize real estate, and invite companies to conferences. Far fewer examine the accumulated delays embedded in ethics review, regulatory sequencing, contracts, tax treatment, immigration, procurement, and hospital governance.

Australia’s success suggests that regulatory design can be more valuable than promotional spending. A country does not need to dominate every stage of drug development. It needs to identify a stage where it can become exceptionally fast, cost-efficient, scientifically credible, and internationally compatible.

For early clinical development, predictability is nearly as valuable as raw speed. Sponsors can plan around a known review cycle. They struggle with systems where nominal timelines are short but actual decisions depend on opaque queues, repeated questions, or unofficial institutional practices.

The combination of CTN, competent HRECs, high-quality sites, a chronic-disease-relevant population, and a refundable R&D offset gives Australia a defensible position. Other countries can copy individual components. Reproducing the full institutional trust accumulated over decades is harder.

This article is a strategic and historical perspective, not investment, medical, regulatory, legal, or tax advice. Trial sponsors should obtain current specialist guidance and verify eligibility, timelines, and regulatory requirements for each program.

Honoring the People Who Built the System

Earle Page helped establish an early federal foundation for therapeutic substance standards through the 1953 legislation. The Hawke government and the public servants behind the Therapeutic Goods Act 1989 built the statutory basis for the modern TGA. Peter Baume subjected the emerging system to a broad, serious review through A Question of Balance, and Richard Day helped test and consolidate the CTN model during its early operation.

Peter Staples deserves the clearest recognition. As federal Minister for Aged, Family and Health Services, he announced the Clinical Trial Notification scheme in February 1991 and commissioned the Baume review. Those decisions helped create one of Australia’s most durable and internationally competitive biomedical policy assets.

Today, Minister Mark Butler and the federal health portfolio inherit responsibility for that asset. The TGA, HREC network, state and territory health systems, hospitals, universities, trial units, and working clinical teams maintain it one protocol and one participant at a time. Their earned achievement is a system capable of moving rapidly without making speed the enemy of trust.

Insilico Medicine uses this system because it works. As a global, multi-hub company advancing a growing AI-generated and AI-enabled pipeline, we need jurisdictions where rigorous human testing can begin without avoidable delay. Australia earned that role through the foresight of named individuals, the competence of institutions, and the continuing labor of people whose contribution is rarely visible outside the clinical research community.

The biotechnology revolution is usually narrated through founders, scientists, venture capital, and breakthrough medicines. Australia’s experience shows that regulatory architects belong in that history as well. The medicines generated by the next era of artificial intelligence will still depend on the policy infrastructure they created, and on the officials and clinical professionals now responsible for preserving and improving it.